Cost-effectiveness of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease in the UK (2012)
Yang Meng
Hazel Squires
John Stevens
Emma Simpson
Steve Thomas
Jonathan Michaels
Gerard Stansby
Mark O'Donnell
10.15131/shef.data.11913492.v1
https://orda.shef.ac.uk/articles/poster/Cost-effectiveness_of_cilostazol_naftidrofuryl_oxalate_pentoxifylline_and_inositol_nicotinate_for_the_treatment_of_intermittent_claudication_in_people_with_peripheral_arterial_disease_in_the_UK_2012_/11913492
<p>The study aims to assess the cost-effectiveness of the
vasoactive drugs cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol
nicotinate for intermittent claudication due to peripheral arterial disease
(PAD) in adults whose symptoms continue despite a period of conservative
management.</p>
<br>
2020-02-28 11:41:42
peripheral arterial disease
cilostazol
naftidrofuryl oxalate
inositol nicotinate
Health Economics